The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N

British Journal of Cancer

Volumn 85, Issue 4, 2001, Pages 625-629

  Gallagher, R ^a   Hughes, C M ^a   Murray, M M ^a   Friery, O P ^a   Patterson, L H ^b   Hirst, D G ^a   McKeown, S R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

AQ4N + cisplatin; Chemopotentiation

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; CISPLATIN; TIRAPAZAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MICE; PRODRUGS; TRIAZINES;

EID: 0035902851     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1975     Document Type: Article

References (21)

1. Tumour-specific schedule dependent interaction between tirapazamine (SR4233) and cisplatin
2. Modification of the anti-tumour activity of chemotherapy drugs by the hypoxic cytotoxic agent tirapazamine
3. Enhancement of the antitumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine
4. Human CYP2B6: Expression, inducibility and catalytic activities
5. DNA damage following combination of radiation with the bioreductive drug AQ4N: Possible selective toxicity to oxic and hypoxic tumour cells
6. Enhancement of alkylating agent activity by SR4233 in the FSaIIC murine fibrosarcoma
7. Enhancement of melphalan - Induced turnout cell killing by misonidazole: An interaction of competing mechanisms
8. Hypoxic cells as specific drug targets for chemotherapy
9. Hypobaric hypoxia: A method for testing bioreductive drugs in vivo
10. AQ4N: An alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo
11. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation
12. The dynamics of tumour cords in an irradiated mouse mammary carcinoma with a large hypoxic cell component
13. The potential of using hypothermia to eliminate radioresistant hypoxic cells
14. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: A new class of bioreductive agent
15. Involvement of human cytochrome P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug
16. Potentiation of cisplatin activity by the bioreductive agent tirapazamine
17. DNA topoisomerase II dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides
18. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells
19. Comparative chemosensitivity of exponential-versus-plateau phase cells both in vitro and in vivo
20. A new mouse tumour model system (RIF-1) for comparison of end-point studies
21. Guidelines for the welfare of animals in experimental neoplasia (second edition)